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1. Introduction 
Development and maturation of the human brain especially genesis of neurones and 
synaptogenesis are under the genetic control of neurohormones secreted by hypothalamus 
during fetal and early postnatal life. So the lesser modification in the hormonal status might 
influence either the neurodevelopment course or the sexual differentiation. This study shows 
that there are serious effects on the psychological and physical health of the descendants of 
women treated with synthetic hormones during their pregnancy. Preliminary results by a 
group in Paris have recently been published [1], based on observations and diagnoses of 
psychiatric disorders in a small sample of children from the HHORAGES families. As 
synthesized by Dodds in 1938, but not patented, diethylstilbestrol (DES), a synthetic non-
steroid estrogen, given among others to pregnant women, was considered at the time as “an 
indisputable progress in the therapeutics of ovarian deficiency”, and was described in such 
terms as early as May 1939 in an advertisement shown in “Le Progrès Médical”, a French 
journal. Despite various alerts which were published as early as 1940, and after research work 
was conducted on animals proving carcinogenic effects, and despite Dieckmann et al. [2], 
which demonstrated the ineffectiveness of DES to prevent miscarriages or premature births in 
a large cohort of DES-treated women versus placebo-treated women, the product has been 
much used worldwide, and has caused a long list of damaging effects in the past, the present 
and very likely in the future [3-5]. The discovery of vaginal clear cell adenocarcinomas in “DES 
daughters” [6] led to DES being banned for pregnant women in 1971 in the US, but it was only 
in 1977 that it was banned in France, where this particular use of DES was removed from the 
Vidal pharmaceutical handbook. However, DES was still sporadically prescribed until 1981. 
Meanwhile, another steroid estrogen, also synthesized in 1938 by H. Herloff Inhoffen and W. 
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Hohlweg, 17-alpha-ethinylestradiol, was often added to DES in cocktails, or at a later stage 
was used as a replacement, sometimes with synthetic delayed progestin. An example of 
prescription, time and doses is shown in Table 1.  
History: Miscarriage, two years before, at 6 weeks amenorrhea.
1st pregnancy: 1966-67. At 7 weeks amenorrhea: Ethinylestradiol (EE) 100mg/d. From 10th 
to 20th week: Distilbene 25mg/d + EE 100mg/d. From 20th to 37th week: Distilbene 15mg/d 
+ EE 250mg/d+ Delay Progestin 500mg/week. Full term delivery: girl, 3,870kg weight, 
Apgar score 10/10. No problem during pregnancy and delivery. 
2nd pregnancy: 1970-71. At 6 weeks amenorrhea: EE 500mg/d. From 8th to 37th week: EE 
500mg/j + Distilbène 25 mg+ Delay Progesterone 500mg/d. Full term delivery, boy, 3,900 
kg weight, Apgar Score 10/10. No problem during pregnancy and delivery. 
Twenty years after: 1stchild (girl): Recurrent depressions and eating disorders, 14 suicide 
attempts, then suicide in 1995 (28 years old). 2ndchild (boy): Borderline Schizophrenia. 
Suicide in 1998 (27 years old).
Table 1. An example of synthetic hormone prescription during two successive pregnancies (dose and 
exposure periods), confirmed by medical file and its “20 years after” consequences (MOSG personal data). 
As visible in Table 1 the doses/kg/day prescribed to this pregnant woman for her first 
pregnancy were: ethinyl-estradiol (EE): 19µg/kg-1/d; DES: 28.8µg/kg-1/d; Progestin delay: 
1,37 mg/kg/d. For the second pregnancy, prescribed doses were slightly higher except for 
synthetic progestin delay prescribed at identical dose. Similar doses were administered to 
other pregnant French women and in the whole world, not only to women who had 
miscarriages (as the prevalent idea at the time was that they suffered from a hormonal 
deficiency which caused the miscarriage, whilst it is well known nowadays that the 
deficiency is caused by the miscarriage itself), but also to other women as a pain-relieving 
medicine, or even as a morning-after pill or for comfort.  
Although DES and 17-alpha-ethinylestradiol belong to different estrogenic categories (non-
steroid and steroid) and degrade in different ways, they do bind to the same ER-beta-
estrogen receptors. The (natural) 17-beta-estradiol belongs to the family of steroid estrogens, 
which are lipophilic compounds. So it should bind to lipids, but thanks to the 
metabolization enzymes Cytochromes P-450 [7] it will be disposed of in the form of 
hydrosoluble products such as estriol, which can be found in the urine in the sulphate form. 
The (synthetic) 17-alpha-ethinylestradiol undergoes different metabolization pathways 
relative to its acetylenic function. These pathways deactivate the metabolization enzymes 
Cytochromes P-450, unlike the hydrosoluble natural estradiol, estrogen, which degrades in 
estriol. Hence the 17-ethinylestradiol remains bound to the lipids. Diethylstilbestrol, a non-
steroid oestrogen, is a very lipophilic synthetic diphenol. Its metabolization is also different 
from natural estradiol; it is a molecular degradation by means of a very harmful oxidation 
reaction, as it will release toxic “quinone”-type structures, which are highly reactive to 
proteins and to DNA in particular (Table 2). 
Up to now, many research studies have been carried out on animals (mice and rats), showing 
the toxicity of such synthetic oestrogens upon the descendants, and inducing in particular 
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behavioral disorders – along with other effects such as cancers [8,5] with multigenerational 
carcinogenesis effects on mice (9). Prenatal exposure to three different synthetic chemicals, 
DES and two pesticides (DDT and its chemical analogue, methoxychlor), was studied [10]: it 
affects the behavior of young mice, showing increased aggressiveness in males (increase of the 
number of attacks and decrease in reaction time before the attack). However, the DES doses 
were 1000 times smaller (0.02 and 0.2 µg/kg) than the DDT ones (and analogue) (20 and 
200µg/kg), while the subsequent aggressive reactions were far more severe, showing the 
tremendous impact of DES, even at low doses. The treatment period of the mothers from the 
11th to the 17th day of the gestation also played a key role, as it represents a crucial period in the 
differentiation of the reproductive system and in the development of the brain in the rodents 
studied [11]. Newbold [4] unambiguously demonstrated the validity of the “rodent model” 
transposed to humans. Injection of 17-alpha-ethinylestradiol (EE) in pregnant rats not only 
induces many abortions, but also anxiety and depression-type disorders in pups (strain Dark 
Agouti) [12, 13] (15µg/kg-1/d). In terms of brain cytology, an alteration of the frontal part of the 
hippocampus in young rats (Long Evans strain) which were EE-treated in utero was also 
demonstrated [14] at the same doses which were calculated to be relatively comparable to the 
doses prescribed to pregnant women (see Table 1). 
 
The (natural) 17-beta-estradiol belongs to the family of steroid estrogens, which are 
lipophilic compounds. So it should bind to lipids, but thanks to the metabolization enzymes 
of the Cytochromes P-450 type, it will be disposed of in the form of hydrosoluble products 
such as Estriol, which will be found in the urine in the sulphate form.  
The (synthetic) 17-alpha-ethinylestradiol undergoes different metabolization pathways 
relative to its acetylenic function. These pathways induce the inactivation of the 
Cytochromes P-450. Hence the 17-Ethinyl-Estradiol will remain bound to the lipids.  
The diethylstilbestrol, a non-steroid estrogen, is a very lipophilic synthetic diphenol. Its 
metabolization is also different from natural Estradiol; it is a molecular degradation by 
means of a very harmful oxidation reaction, as it will release toxic “quinone”-type 
structures, which are highly reactive to proteins and to DNA in particular.
Table 2. Difference between natural sexual hormone, the 17-beta-estradiol type, and the synthetic 
hormones of the 17-alpha-ethinylestradiol or diethylstilbestrol type. 
In humans, research work on the effects of synthetic hormones on women is scarce, but as 
early as 1977, June Reinisch [15] published a paper in Nature showing that the personality of 
the children whose mothers had been treated with synthetic oestrogens and progestin could 
be affected. Behavioral disorders starting in post-adolescence have since been reported in 
the children exposed in utero to the two mentioned estrogens: depression [16, 17], anxiety 
[17- 19], schizophrenia [20, 21], anorexia and bulimia [22]. These observations were 
summarized by Pillard et al [17] and Verdoux [21]. As early as 1987, was described [20] the 
case of 4 male adults prenatally exposed to DES and showing psychotic disorders. It is only 
during late adolescence that psychotic disorders develop, which often requires a neuroleptic 
treatment, even in the absence of family history of same. They hypothesized then that there 
could be a causal relationships between disruptions in the neuro-development linked to DES, 
and the subsequent appearance of psychotic disorders. Pillard et al. [17] showed that the 
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frequency of major recurrent depressive episodes was significantly higher in DES sons than in 
their unexposed brothers, which was recently confirmed in 2010 [23] in DES daughters from a 
cohort of 74,628 women (known as “Nurses Health Cohort”), 1,612 of whom were exposed to 
DES. In critical literature reviews Kébir and Krebs [24, 25] analyse in particular the results of 
the only three epidemiological large cohort studies, as well as smaller cohorts in relation to the 
effects of DES on the onset of psychiatric disorders. Out of the three epidemiological studies on 
large cohorts, two favour the hypothesis of an existing causal link [18, 23], and one reaches a 
different conclusion (study based on 1,352 mothers) [26].  
The mothers’ exposure to synthetic hormones, and in particular to DES and 17-alpha-
ethinylestradiol, during pregnancy, and the study of its impact on exposed children, 
represents an almost experimental model to evaluate the toxicity of these products: the 
French HHORAGES troop, the results of which are presented in this work, is a “real-world” 
experimental group, in real-life conditions. 
2. Materials and methods: Gathering questionnaires and the evidence  
This study is not epidemiological. Its purpose is to put together a database that will enable 
HHORAGES-France to advance the evidence of serious effects on the psychological and 
physical health of the descendants of women treated with synthetic hormones during their 
pregnancy. This study has been carried out based on spontaneous testimonies from families 
affected. Families were alerted to this initiative either by TV, by radio, or by direct 
confidential communication. After an initial contact with the association (by phone, post, or 
via e-mail), a detailed questionnaire (Table 3), prepared by researchers and doctors, was 
sent without consideration of race only to the families affected by psychiatric disorders in 
one or more of their children with or without somatic problems. More often mothers 
answered but also daughters or sons if the mother was deceased or too old or ill or in denial 
of the effects. Concerning the age of the children, psychiatric diseases appearing generally at 
the post adolescence after 18 years or later, testimonies concern people born between 1946 to 
2000. In order to avoid some deviations in the sample, other factors as contamination with 
pesticides or other chemicals were questioned in the paragraph “professional exposure”. 
An authorization request about such questionnaires and files was sent to the CNIL (French 
“Commission Nationale de l’Informatique et des Libertés") and obtained. Subsequently the data 
were synthesized in the form of synoptic data for further studies. In 2006 a first detailed 
analysis of 2002-2004 and 2005 data was carried out in the Laboratoire d’Endocrinologie-
Pédiatrique of the Montpellier University Hospital (CHU Lapeyronie), and was conducted 
according to specific descriptive criteria: exposed and unexposed children, daughters and 
sons, ranking in the sibling order, treatment by synthetics (oestrogens, oestrogen-progestin, 
or progestin), and pathologies, malformations and other disorders. In May 2009, all files 
with prescriptions attached were validated in psychiatric terms by representatives of the 
CERC (Centre d’Etude et de Recherche Clinique, Hôpital Sainte-Anne, Paris, run by Professor 
M.O. Krebs), a research laboratory with which HHORAGES established a partnership from 
2007 via a PICRI project (Partenariat Institution Citoyen pour la Recherche et l’Innovation) 
subsidized by the Île-de-France region, and for the benefit of said Laboratory. 
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Mother’s Situation: Surname, First Name, Date of Birth, Address, Home phone number, 
Professional phone number, Mobile number, E-mail address 
Family Situation, Number of children, children’s first names and dates of birth. Professional 
Situation.  
Pill taken: before first pregnancy, and between pregnancies 
Hormonal treatment before pregnancy (or pregnancies). (If a treatment was prescribed, 
please indicate the nature of the treatment and the time elapsed between the end of 
treatment and the beginning of the pregnancy) 
Miscarriage(s): Indicate the time when it occurred, in relation to the other full term 
pregnancies, if any (before the first one, or between two full term pregnancies?)  
Professional Exposure to hormones, to chemicals (pesticides, etc...) 
Psychiatric or psychopathological family history (father, mother, …) 
Health problems after first child birth  
Pregnancy and childbirth (For more than 2 children, T.O.P.)  
1st child                2nd child  
Treatment during pregnancy: (Yes/No) - Nature of medicines - Doses – What time during 
pregnancy (first and last day of treatment, expressed in weeks from the beginning of 
pregnancy)? 
What medical reason was put forward (possible miscarriage, comfort, etc...)? 
At what month did the delivery occur, from the start of the pregnancy? 
General condition of the child, Sex, Weight, Health problems at birth (mother and child) 
Existing documents (prescriptions, medical files, etc...) and testimonies 
Would you be so kind as to send us the copies of the files and documents? If yes, in order to 
save time, please attach the copies of all relative documents in your possession. 
Health problems of your children (For more than 2 children, T.OP) 
1st child,  2nd child First name, Sex, Birth Date, Rank in the sibling order 
Physical disorders: Which ones? What age? Sterility treatment? Surgery? 
Psychological disorders: Nature of first symptoms? What age? Subsequent aggravation? And 
at what age? 
Other data: Hospitalization, Violence, Suicide attempt(s), Medical Treatments, Diagnosis, 
AAH, Disability? 
Relational difficulties: in married life, in professional life? 
Children, grandchildren: How many? Full term? Health condition? Malformations or 
observed disorders? 
Table 3. Questionnaire sent to families. 
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3. Results 
3.1. Data analysis  
Chronological evolution of number of cases issued from the HHORAGES-France association 
was studied from testimonies collected from 2002 to 2007 (Figures 1-4). From 2002 
(foundation of the HHORAGES association) to 2004 our first crude analysis was based on 
the testimonies of 297 mothers with a total number of 511 children, the birth years ranging 
from 1946 to 1994 (Figure 1). 161 unexposed children had no disorder (“control”), 35 
children exposed in utero had no disorder, 297 children exposed in utero showed various 
psychiatric pathologies, while 18 unexposed children also showed psychiatric disorders. It 
must be noted that in most families without any psychiatric antecedent and having several 
children, only the exposed child showed psychiatric disorders.  
 
Figure 1. Representation of case numbers as a function of administered or not synthetic hormonal 
treatments during pregnancies (children born between 1946 and 1996), in a cohort of 511 children born 
from 297 mothers. The x-axis shows the birth years and the y-axis the number of cases. A prescription 
peak can be observed in the seventies. Black line: children exposed in utero with psychiatric disorders; 
dotted line: children unexposed without any disorders; dash line: children exposed in utero without 
psychiatric disorders; thick grey line: unexposed children with psychiatric disorders (HHORAGES-
FRANCE data 2002-2004).  
In 2005, a larger overall analysis based the testimony of 470 mothers (Figure 2) with a total 
number of 967 siblings: 381 of whom were not exposed, 345 exhibited no disorder, and 18 of 
whom showed psychiatric disorders. Interestingly, 9 of those unexposed with psychiatric 
disorders were born after their mother had been treated with synthetic hormones during a 
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previous pregnancy. 586 children were exposed, during their mother’s pregnancy, to DES 
only or to DES in association with synthetic ethinylestradiol, and sometimes with synthetic 
delayed progestin, 538 children displayed psychiatric disorders and 35 were without any 
psychiatric disorders nor any malformation whatsoever and 13 were stillborn.  
 
Figure 2. A detailed representation of case numbers in a group of 967 children born from 470 mothers. 
363 unexposed children do not present any disorder. 586 children were exposed in utero, 48 of whom 
without disorders and 538 with psychiatric disorders (PD). 18 unexposed children showed PD, 9 of 
whom after their mother was treated in a previous pregnancy. Thin grey line: children exposed in utero 
with psychiatric disorders collected in 2004; black line: children exposed in utero with psychiatric 
disorders (2005). Thick grey line: unexposed children with psychiatric disorders. Dash line: Suicides and 
series of suicide attempts of in utero exposed children with psychiatric disorders. Comparison between 
2004 and 2005 curves and suicide curve show the same prescription peak than in Fig.1 as observed in 
the seventies (1971) (HHORAGES-France data 2005). 
By refining these observations, it appeared that out of the 538 children exhibiting psychiatric 
disorders, 200 suffered also from genital malformations. However, 74 presented genital 
malformations or other somatic disorders only, whereas 126 exhibited somatic and 
psychiatric disorders. In total, 538 children had psychiatric disorders. There were 18 non-
exposed children who presented psychiatric disorders, 9 of which after their mothers had 
been exposed in a previous pregnancy. Among the children showing psychiatric disorders, 
it must be stressed that a significant number of suicides (22 S) and 90 series of suicide 
attempts were observed (dash line curve). The comparison between the 2004 and 2005 
curves represented on Figure 2 shows a homothety, the peak of children suffering 
psychiatric disorders being for children born on the 1971-1972 years as well as the peak of 
suicide and suicide attempts. 
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In 2006-2007, a detailed analysis covered 529 testimonies, representing a total number of 
1182 children as shown in the synthetic tree diagram of Figures 3.  
 
Figure 3. Tree diagram showing the distribution of a cohort of 1182 children born from 529 mothers, 
740 of whom were exposed to synthetic hormones during their mothers’ pregnancies. 41 exposed 
children did not show any disorder, 15 were stillborn and 684 were affected either by psychiatric 
disorders only, or by somatic disorders only, or by both (HHORAGES-France data 2006-2007). 
442 children were not exposed, of which 422 did not exhibit any disorder or malformation; 
while 20 whose mothers had been exposed in a previous pregnancy exhibited psychiatric 
disorders. Among the 740 who were exposed in utero, 15 were stillborn (10 boys and 5 girls), 
41 were not affected (25 boys and 16 girls) and 684 were affected, 405 of which with 
psychiatric disorders only, 198 psychiatric disorders associated with genital malformations 
and other somatic disorders, and 81 were affected only physically.  
In Figure 4 is shown the ratio of Boys/Girls, as well as their numbers. Thus 740 children 
were exposed and 684 were affected either by psychiatric disorders only, or by somatic ones, 
or by both. 65 girls and 16 boys were affected by somatic disorders only, while 134 girls and 
64 boys were affected by psychiatric and somatic disorders. 219 girls and 186 boys are 
affected by psychiatric diseases only. Our group of 1182 total children is composed of 630 
girls and 552 boys, so the gender ratio is 1.14. For children suffering from psychiatric 
diseases only, gender ratio is 1.17, psychiatric and somatic disorders 2.09, and somatic 
disorders only, 4.06.  
Among the 442 “non-exposed” pregnancies, 422 children were not affected and 20 (mothers 
previously treated) were affected presenting psychiatric and/or somatic disorders. Among 
the 422 not affected 182 are free from all exposure (104 boys and 78 girls) and 240 were born 
after their mother was treated in a previous pregnancy (123 boys and 117 girls); so we 
observed a majority of unaffected boys. Among the 20 affected are 14 girls and 6 boys. Of 
these 14 girls, 7 suffered psychiatric disorders only, 3 presented psychiatric and somatic 
disorders, 4 somatic disorders only. Of the 6 boys, 4 presented psychiatric disorders, 2 
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psychiatric and somatic, and none with somatic disorder only. It is clear overall that 
disorders in girls are more numerous than in boys.  
 
 
 
 
Figure 4. Detailed testimony group included in the study showing the distribution of girls and boys of 
second generation in a cohort of 1,182 children born from 529 mothers: 740 of whom were exposed to 
synthetic hormones during their mothers’ pregnancies collected from 2002 to 2007. 15 were stillborn 
and 684 were affected either by psychiatric disorders only, or by somatic malformations only, or by both 
(HHORAGES-FRANCE data 2006-2007). In all cases girls suffered more than boys either from 
psychiatric, and/or somatic disorders, while boys are more likely than girls to be unaffected even after 
exposure: 41 exposed children did not show any disorder (25 boys versus 16 girls) (HHORAGES-France 
data 2006-2007). 
For boys among somatic disorders associated or not with psychiatric disorders (on a total of 
80 boys), we have counted 28 cryptorchidia, 22 hypospadias, 14 sterility, azoospermia or 
semen abnormalities, 12 cancers or others, 4 micropenis. (Figure 5). 
Among a total of 210 girls, somatic disorders associated or not with psychiatric disorders 
are: 70 womb malformations, 50 sterility, 31 difficulty to procreate (primary and secondary 
infertility), miscarriage, extra uterine pregnancies, 31 cancers (often of breast) or others, 21 
ovarian cysts, 8 endometriosis. (Figure 6). 
As of today (April 2012), we are receiving an ever-increasing number of testimonies, the 
total number of testimonies collected by HHORAGES is 1,223, which represents 2,674 
children from them 409 unexposed, 1,676 children exposed to synthetic hormones after 
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medical prescriptions and 589 (post-DES) born after a previous exposure from which 20 
presented psychiatric and/or somatic disorders. Amongst this total amount of 1,676 exposed 
children, 1,549 children are affected: 916 present psychiatric disorders, 418 somatic plus 
psychiatric disorders, 183 somatic disorders, 126 exposed are non affected. In addition, we 
numbered 48 suicides and 128 series of suicide attempts. Many HHORAGES families 
collaborated in genetic and epigenetic studies, as carried out in the Inserm U796 Laboratory 
in St-Anne Hospital, Paris, in order to understand the cellular and molecular mechanisms 
disrupted by these xenooestrogens [1] in the cadre of the PICRI (Partenariat Institution 
Citoyens pour la Recherche et l’Innovation) project. In addition, the HHORAGES families 
participate to a vast study on the origin of schizophrenia, this study, granted by the French 
National Research Agency (ANR), is larger than the PICRI one and also developed in the St 
Anne Hospital, Paris, by the Professor M.O. Krebs team. 
 
 
Figure 5. Somatic disorders in boys after exposition to synthetic hormones (DES, EE,.). Cryptorchidia 
and hypospadias are the most numerous disorders. These disorders are whether or not associated with 
the psychiatric ones (HHORAGES-France data 2007). 
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Figure 6. Somatic disorders in girls after exposure to synthetic hormones (DES, EE,). Womb 
malformations and sterility are the most numerous disorders. These disorders are whether or not 
associated with psychiatric ones (HHORAGES-France data 2007).  
4. Discussion  
1. Research work on behavioral disorders in humans after prenatal exposure to synthetic 
hormones is scarce, as people affected by severe psychotic disorders and their families 
are not usually very inclined to answer epidemiological inquiries. Similarly, as 
suggested in a preliminary work [27] the number of families who spontaneously gave 
their testimony to HHORAGES (more than 1220 to date) is rather low in comparison to 
the total number of pregnancies effectively treated with these products, about 160,000 in 
France according to [28,29]. Nevertheless, in our results presented in Figure 2, we 
observe in addition  to the fact that curves deducted from successive year data are 
homothetic and that the peak of the curve representing children suffering psychiatric 
disorders as well as the peak of suicide and suicide attempts correspond to the years 
1971-72. This could be put in parallel to the curve published in Figure 1 in [28] and 
calculated from the DES plaques sold in our country (EE sold plaques not estimated).  
But some testimonies remained anonymous, or some families were not properly 
informed, or failed to answer the questionnaires, in these cases, certain factors should 
 
State of the Art of Therapeutic Endocrinology 78 
be taken into account: -The fact that psychiatric disorders appear during post-
adolescence implies on average a twenty-year gap between the time when the mothers 
were treated and the appearance of the disorder, hence the difficulty finding the 
prescriptions and the medical files.– Psychiatric disorders are often treated with denial 
and shame, which presents problems connecting families with HHORAGES, or in their 
answering any inquiry whatsoever; and the children (DES sons and daughters for 
instance), if and when they are informed (often very late) about their family (mother) 
history, they first try to find a cure, as psychotic disorders can often be very 
incapacitating, especially if these disorders are in addition to genital malformations, 
sterility, semen abnormalities or total azoospermy. 
2. Somatic disorders of boys and girls as genital malformations (see Figures 5 and 6), 
sterility, azoospermie, endometriosis, cancers, are now completely recognized as being 
a consequence of DES or EE in utero exposure. In our troop, they are found associated 
with psychiatric disorders for 198 children, while 81 were only somatically affected. The 
total amount of 279 children represent more than 1/3 of the 684 affected children 
exposed to synthetic estrogens that demonstrate the DES and EE signature.  
A preliminary result concerning a small part of the total number of children linked to 
the HHORAGES families was published in 2009 in a congress communication [1] 
(Table 4). A series of cases were studied, consisting of 31 files about 31 mothers and 72 
children born alive. Among the 72 children, the following were found: 43 children 
exposed and affected, 4 exposed, but not affected, 23 non-exposed and not affected, 1 
non-exposed but affected. The involved hormones were DES and 17-alpha-
ethinylestradiol and synthetic progestin. The psychiatric disorders found were: Alcohol 
addiction: 3, Learning disorders: 3, Eating disorders: 9, Behavioral disorders 
(aggressiveness, impulsivity): 5, Sleeping disorders: 3, Anxiety disorders: 7, Mood 
swings: 12, Major depressive episodes: 2, Bipolar disorders, Personality disorders: 3, 
Schizophrenia: 10, Acute psychotic episodes: 4, Series of suicide attempts: 9, and 
Suicides: 5. As concluded in this communication “The clinical pictures relative to the 
children studied are quite complex and involve some atypical associations, for instance 
mood swings associated with psychotic features.” A larger study pertaining to this 
cohort is under way. 
It is known that psychosis as schizophrenia for example affects about 1% of the world 
population, a few part being of genetic familial origin. Neuro developmental and 
environmental causal factors of schizophrenia (or of other psychoses as bipolar 
diseases) are yet badly known, the epigenetic track and the conjunction gene X 
environment theory being the best hypothesis from several years [24, 25, 30]. So the 
HHORAGES family group participates also to a study largest than PICRI on the origin 
of schizophrenia also developed in the St Anne Hospital by Professor M.O. Krebs team.  
3. In this study, we observed that girls seem more vulnerable to synthetic estrogens than 
boys either for somatic and psychiatric disorders (see Figure 4). The preferential effects 
of DES on female versus male are not fully understood. It is likely that prenatal DES 
exposure affected behavior through its action on estrogen receptor alpha or beta of the 
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hypothalamic area which concentration may be higher in female fetus as shown in [30]. 
A sex difference in DNA methylation and gene regulation after prenatal DES exposure 
cannot be excluded [31] and last, hypomethylation of COMT promotor, a major risk 
factor for schizophrenia and bipolar disorder, may be different between male and 
female fetus and infant [32]. Our observations are reinforced by these of Braun et al [33] 
about BPA exposure and cognitive disorders or hyperactivity observations in in utero 
exposed children. In their study authors observed this BPA exposure affected 
behavioral and emotional regulation domains from 3 years of age, especially among 
girls which present aggressiveness and impulsivity. Authors suggest that girls would 
be more sensitive than boys in utero to BPA, which acts as mimetic of natural estrogen 
hormones, and in surplus to them.  
 
Among  the 72 children born alive, 40 exposed children were affected, 7 exposed were not 
affected, 1 exposed but deceased by the age of 10 months, 23 children were not exposed 
and not affected, et 1 unexposed child was affected. The psychiatric disorders are as 
follows :  
Alcohol addiction: 3; Learning disorders: 3; Eating disorders : 9 
Behavioral disorders (aggressiveness, impulsivity): 5 
Sleeping disorders: 3; Anxiety disorders: 7  
Mood swings: 12; Major depressive episodes, 2 
Bipolar disorders, Personality disorders: 3  
Schizophrenia: 10; Acute psychotic episodes: 4  
Series of suicide attempts: 9 and Suicides: 5.  
Table 4. Analysis of the psychiatric cases of 72 children from 31 testimonies [1]. From this observation, 
authors suggest that the vulnerability toward psychiatric disorders could be enhanced after 
impregnation with diethylstilbestrol (DES), ethinyl estradiol and/or synthetic delay progestin during 
the mother’s pregnancy. 
Concerning the manifestation of psychiatric disorders in boys and girls, appearing often 
post adolescence, Verdoux [21] had suggested that these diseases could be due to the 
exposed status of the children after being informed of it by the mother: In our cohort, 
during our contacts with families, we carefully questioned them about this point: most 
of children had never been previously informed of the exposure, or were never 
informed at all. 
Concerning the 41 children exposed and not affected (25 boys/16 girls) and the 422 
children unaffected (226 boys/196 girls) of which 242 mothers had been treated in a 
previous pregnancy, a majority of boys is observable: we think that this fact could be 
linked to the specific and unequal detoxification potential of each individual, and could 
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concern either the treated mother or/and the fetus in correlation with Cytochromes P450 
gene activity and their regulation, as well analysed in the recent work of the Seralini 
group [34].  
Concerning the 20 boys and girls (14 girls and 6 boys) “post DES” (whose mothers were 
only exposed during a previous pregnancy) and suffering psychiatric and somatic 
disorders, this could be linked with the lipophily (see Table 2) of the synthetic estrogens 
(DES and/or EE) administrated to mothers during a previous pregnancy, due to their 
likely residuum (remanence) in the maternal tissues.  
4. There is a large amount of convincing research on animals (rodents) showing an 
indisputable link between synthetic estrogen exposition during gestation of the females 
and various disorders in exposed pups. Newbold et al [35] did not hesitate to 
extrapolate from rodents to humans where anatomical disorders observed in older mice 
are concerned after they were prenatally exposed to DES (cancers, lesions of the male as 
cryptorchidism, testicular hypoplasia, semen abnormalities [36] or female genital 
abnomalies, also of DNA and genetic lesions) as well as a function of the doses as of 
exposure time. She believes that the DES makes an excellent predictive model for other 
environmental estrogens. Indeed, O’Reilly et al. [23], in their epidemiological work on 
the depression rates in DES daughters, suggest that studies on this pathology may be 
extrapolated to children exposed to BPA in utero. Endocrine disrupter Bis-Phenol A 
(BPA) was nearly chosen instead of DES, but ultimately was not. However, its action 
inside plastic materials is even more insidious, as it is present in a large number of 
materials and consumer goods and as it contaminates therefore the whole population, 
including fetuses and infants via their breast feeding mothers. Among the many 
research works carried out on animals (rats, mice, monkeys) showing that there is a 
detectable effect for doses lower than the ADI (Acceptable Daily Intake) of 50µg/kg, one 
is specially interesting: it has been demonstrated in mice, that a prenatal exposure to the 
low dose of 10µg/kg (from the 11th day of gestation) unambiguously triggers behavioral 
disorders, besides other effects [37]. As recently published [38] the effects of low dose 
cannot be predicted by the effects observed at high doses. And as far as some 
organophosphate pesticides that mimic oestrogens are concerned, it has been recently 
shown that residues of such chemicals in urine samples of 1139 children aged 8-15 came 
from the family food (based on garden fruits and vegetables), and that their presence 
was strongly correlated to behavioral disorders of hyperactivity type and cognitive 
disorders (attention deficit disorder) type [39].  
5. A multi-generational effect? By what mechanism?  
Multi-generational carcinogenesis studies were realized on mice after diethylstilbestrol 
impregnation with impressive and undisputable results [8, 9]. Our observations presented 
in this present work from the French HHORAGES troop raises the question of the 
mechanism through with synthetic hormones as DES cause either psychiatric disorders in 
exposed children and/or adverse effects in subsequent generations. Since Abdomaleky et al 
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[40,41,30] concluded that modulation of gene-environment interactions may be trough DNA 
methylation, in [42] and [24, 25] authors put forward hypothesis that DES-induced changes 
in epigenetic background and alteration of DNA methylations could be significant factors. 
The pregnant mother’s exposure to DES at very early neurodevelopment time and/or at time 
of sex determination would appear to be sufficient to alter the remethylation of neuron 
precursors and/or of the fetus germ line. Only a few third-generation children suffering 
psychiatric illness are mentioned in testimonies. This is understandable because third 
generation exposed children are still too young (excepted in some cases) to present 
psychiatric disorders as schizophrenia which is not the case for hypospads that are 
detectable from birth in male children and grand-children [42]. Work is already under way 
concerning the gene X environment DES impact hypothesis by comparing DES and EE 
exposed children, various genetic and epigenetic factors to those of mother and unexposed 
children of the same family as studied by the INSERM team U796 in collaboration with the 
HHORAGES families. 
6. Conclusions 
In the present familial case control study, we have shown that there are serious effects on 
the psychological and physical health of the descendants of women treated with synthetic 
hormones during their pregnancy: psychiatric illnesses are often found associated with 
somatic disorders which are well known to be the DES and EE signature. Synthetic 
hormones, acting as endocrine disturbers, are toxic for humans, especially for pregnant 
women and their children, probably partly in relation with their toxic degradation status. In 
all cases girls suffered more than boys either of somatic and/or psychiatric disorders due to 
the estrogen receptor alpha or beta concentration higher in female fetus than in male. It is 
also clear that in all the families most of the exposed children are ill while quite the 
unexposed are not. 
So what now? As the precautionary principle was not applied in the past, and still is not in 
force today, and since the lessons of recent history were never taken into account [33], it is 
our common duty to repair the damage by supporting the devastated families, and by 
pursuing research work on the observation of trans-generational effects. Such effects are 
already highlighted by the demonstration that cancers are observed even in the fourth 
generation in mice [9]. According to the Skinner’s mini review [43] “the ability of an 
environmental compound (as DES or EE) to promote the reprogramming of the germ-line 
appears to be the causal factor in the epigenetic transgenerational phenotype,” we observed 
an increase of the genital malformations in the third generation in male infants whose 
mothers were treated with xenoestrogens [42]. In the HHORAGES troop, DES and EE-
exposed infants are already pointed out as bodily and/or psychologically impaired after 
their mothers were treated with clomifene citrate (an ovulation stimulator previously used 
for IVF-type medically assisted procreation). Another concern is the putative future effect of 
ethinylestradiol containing oral estrogenic contraception on future generations due to its 
lipophily after its metabolization and its future release in fetus through the placenta. As for 
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the demonstration of the causality link within the HHORAGES troop, will we have to wait 
for a large-scale epidemiological study, or are we allowed to think that the impressive 
figures that we are publishing in this work are not merely random? The only way now is to 
respect absolutely the precautionary principle and to delete completely or to give the less 
possible toxic (synthetic) hormone medication: for example Clavel Chapelon and her 
Endogenous Hormones and Breast Cancer Collaborative Group in Villejuif [44] informed 
that natural hormone as micronized (natural) progestin associated with estrogens (synthetic 
alas!) is more often ordered for SHT (Substitutive Hormonal Treatment) in order to avoid 
breast cancer. Unfortunately, she said also that in the contrary the same SHT is not 
recommended to avoid the endometrium cancer [45]… 
As Newbold et al [35] said after they reviewed the damages caused by DES [4], “only new 
advances in the knowledge of genetic and epigenetic mechanisms of the disruptions of fetal 
development will enable us to be aware of the risks entailed by the other estrogenic 
disruptors which are present around us and in ourselves, even at very low doses”, whilst 
Theo Colborn [46] insists on the fact that the foetus cannot be protected against endocrine 
disruptors, whatever they may be, except at zero level.  
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